🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A lot of talk about patients with borderline renal function (GFR of 40-60 ml/min) that are ? cis-eligible. Here, we present the outcomes of patients from Niagara, showing consistent improvement in EFS and pCR. #AUA2025

Here is the disease-free survival, shown by pCR and non-pCR from Niagara. #AUA2025

Celebrating the election of our amazing Chair of Biochemistry & Molecular Genetics Ali Shilatifard ⁦Shilatifard Lab⁩ to the ⁦National Academy of Sciences⁩. Such a great honor for ⁦Northwestern and ⁦Northwestern Feinberg School of Medicine⁩. Congratulations Ali!

Please join us in congratulating Ali Shilatifard, PhD (Shilatifard Lab), the Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics, who has been elected to National Academy of Sciences. Read the story: tinyurl.com/3kdn5f43

May is Bladder Cancer Awareness Month! 🧡 Throughout the month, we’ll be spotlighting recent episodes focused on this common but often overlooked disease. Stay tuned and help spread awareness! Bladder Cancer Advocacy Network IBCG

Used Eli Van Allen recent AI review to prep for Vogelzang Symposium SWOG Cancer Research Network Dr. Bishoy M. Faltas Cancer Cell

The Future is BRIGHT! Excited for Leslie Ballas bladder preservation trial for responders after NAC. Love this trial, and aligns w much of what we do already. SWOG Cancer Research Network NRG Oncology Kent Mouw

As May is Bladder Cancer Awareness Month, LARVOL CLIN highlights the top 10 trials from the Amer. Urol. Assn. (AUA) 2025. Discover more: t.ly/efSba #LARVOL #AUA25 #BladderCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #CancerCare #MIBC #NMIBC |

One of my favorite things about spring is our annual visiting professor. Now named after Anthony J Schaeffer. This year we hosted James Eastham from Memorial Sloan Kettering Cancer Center. NM Urology.

📢 #ASCO25 | NIAGARA ctDNA Analysis | MIBC pts on perioperative durvalumab: Baseline ctDNA+ in a subset linked to shorter EFS; early ctDNA clearance after D associated with improved DFS; persistent ctDNA post-surgery predicted relapse. Thomas Powles et al. Full abstract →

1/2 ctDNA data for durvalumab+NAC in MIBC from NIAGARA #ASCO25. 57%,22%,9% of pts are ctDNA +ve at baseline/post NAC/post surgery. Poor outcomes for cDNA+ve occur at each time point (HR 0.4,0.3,0.1 respectively). Chemo cleared the ctDNA in most pts & was ⬆️13% with durvalumab

#Niagara study at #ASCO25: Pre-surgery ctDNA is prognostic in perioperative MIBC. Being ctDNA– ≠ pCR, but if ctDNA+ → chances of pCR are close to zero. The real challenge: how should we define clinical CR to potentially avoid radical, mutilating surgery? Brilliant talk by

NIAGARA ctDNA results presented at #ASCO25 🧬 ctDNA is prognostic ➡️ ctDNA negative patients have good DFS and ctDNA positive patient don’t do well Positive ctDNA pre-CX ➡️ negligible pCR ctDNA is making it’s way to clinical care 🩸🧬

👉 Dr. Tom Powles shared the results of the phase 3 NIAGARA trial here at ASCO. Read more about the study and its findings here: buff.ly/tJWHw65 #ASCO25

Trials-in-Progress – Intravesical sacituzumab tirumotecan in participants with intermediate-risk #NMIBC: The phase 1/2 #TroFuse027 study. Presented by Joshua Meeks NM Urology. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4dMVaRk ASCO

Great pleasure during #AUA25 to discuss with Joshua Meeks and Ashish M. Kamat, MD, MBBS the futur of BCG naive field The tremendous IBCG plenary session was fantastic, really enjoyed our debate leaded by Laura S. Mertens urotoday.com/video-lectures…

Joshua Meeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link/e/szAiuFvyaUb

Deeply honored and truly grateful to JedUro1 and Andrew McDonald at @UABMedicine, UAB Urology, and UAB Radiation Oncology for the incredible opportunity to serve as a special visiting professor in Birmingham discussing bladder preservation. Thank you for your generosity and hospitality!